$154 Million is the total value of Corriente Advisors, LLC's 16 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 1000.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MAXR | Buy | MAXAR TECHNOLOGIES INC | $34,124,000 | +89.2% | 1,900,000 | +12.5% | 22.11% | +13.5% |
| SONO | New | SONOS INC | $22,969,000 | – | 1,570,000 | +100.0% | 14.88% | – |
| REPL | New | REPLIMUNE GROUP INC | $12,052,000 | – | 485,000 | +100.0% | 7.81% | – |
| QURE | New | UNIQURE NV | $8,111,000 | – | 180,000 | +100.0% | 5.26% | – |
| OCUL | New | OCULAR THERAPEUTIX INC | $5,998,000 | – | 720,000 | +100.0% | 3.89% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $5,980,000 | – | 460,000 | +100.0% | 3.88% | – |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $1,728,000 | – | 40,000 | +100.0% | 1.12% | – |
| DMAC | New | DIAMEDICA THERAPEUTICS INC | $1,395,000 | – | 201,248 | +100.0% | 0.90% | – |
| PAAS | New | PAN AMERN SILVER CORP | $912,000 | – | 30,000 | +100.0% | 0.59% | – |
| CRDF | New | CARDIFF ONCOLOGY INC | $869,000 | – | 173,361 | +100.0% | 0.56% | – |
| RWT | New | REDWOOD TR INC | $525,000 | – | 75,000 | +100.0% | 0.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CUE BIOPHARMA INC | 8 | Q3 2021 | 26.7% |
| MAXAR TECHNOLOGIES INC | 7 | Q2 2021 | 41.3% |
| REATA PHARMACEUTICALS INC | 6 | Q2 2021 | 29.6% |
| REPLIMUNE GROUP INC | 5 | Q2 2021 | 12.1% |
| APTOSE BIOSCIENCES INC | 5 | Q4 2020 | 18.7% |
| CARDIFF ONCOLOGY INC | 5 | Q2 2021 | 9.5% |
| DIAMEDICA THERAPEUTICS INC | 5 | Q2 2021 | 2.9% |
| TFF PHARMACEUTICALS INC | 4 | Q3 2021 | 15.2% |
| INVESCO QQQ TR | 3 | Q3 2022 | 94.7% |
| LANTERN PHARMA INC | 3 | Q3 2021 | 13.5% |
View Corriente Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cardiff Oncology, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cue Biopharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| TFF Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| NAUTILUS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| Maxar Technologies Inc. | November 26, 2019 | 2,920,750 | 4.9% |
| CATABASIS PHARMACEUTICALS INC | February 23, 2018 | 1,692,899 | 7.3% |
| NEUROLOGIX INC/DE | February 14, 2011 | 16,858,224 | 37.7% |
| AMERICAN VANTAGE COMPANIESSold out | February 16, 2010 | 0 | 0.0% |
| AspenBio Pharma, Inc.Sold out | February 16, 2010 | 0 | 0.0% |
View Corriente Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-15 |
| SC 13G/A | 2022-02-14 |
View Corriente Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.